Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Biological material

Cerebrolysin

Also known as Porcine brain-derived peptide preparation

Clinical — evidence level 4 of 4: Established clinical evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A standardised preparation of peptides and amino acids produced from porcine brain tissue, authorised as a medicine in some countries but not in the UK.

Category
Biological material
Highest evidence level identified
Established clinical evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

Cerebrolysin is not a single peptide but a standardised preparation of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of porcine brain tissue. It is proposed to act by resembling the activity of endogenous neurotrophic factors and by modulating their expression. That mechanism remains a hypothesis: because the preparation is a heterogeneous biological mixture rather than a defined molecule, the active constituents have not been isolated, and the proposed neurotrophic mimicry has not been shown to be the route by which any clinical effect occurs.

Research areas

  • Stroke research
  • Neurodegeneration research

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Present. Cell and tissue work reports upregulation of neurotrophic signalling and anti-apoptotic effects, summarised within the neurotrophic-factor review literature. This is supportive background only and does not establish the mechanism in humans.

Animal evidence

Studies in living non-human animals.

Present, and reviewed within the same literature. Animal work underpins the neurogenesis and neuroprotection claims across stroke, traumatic brain injury and dementia models. It has not been the decisive evidence base, because the compound moved into human trials decades ago.

Human observational evidence

Studies observing people without assigning an intervention.

Present but not the strongest tier available; open-label and registry work exists. Given the size of the randomised literature, observational data adds little.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Substantial, and the distinguishing feature of this compound — but the syntheses are unfavourable. Two Cochrane reviews exist and neither supports routine use. In acute ischaemic stroke, moderate-certainty evidence found no beneficial effect on preventing death, alongside a signal of increased non-fatal serious adverse events. In vascular dementia, reported cognitive improvement was graded very low-quality, with high risk of bias and industry funding across the studies that stated it. Individual manufacturer-funded trials are considerably more positive than the independent syntheses of overlapping data — an unresolved discordance rather than a settled question.

Study limitations

  • The evidence level reflects the volume and quality of randomised evidence, not the direction of the result, which is unfavourable. The Cochrane reviews do not support routine use.
  • Manufacturer involvement is pervasive. Cochrane records that the manufacturer supported three of the multicentre stroke studies, all vascular dementia studies with stated funding had industry support, and the most-cited positive trial was manufacturer-funded with author financial ties.
  • Certainty grading runs the wrong way: it is low where results are positive and moderate where results are null.
  • The 2023 stroke review found that no included study reported poor functional outcome or quality of life — the outcomes patients care about most.
  • As a heterogeneous biological mixture, batch composition is not fully characterised, so the intervention is not guaranteed to be constant across trials or over time.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

Across randomised evidence the preparation does not appear to change all-cause mortality, and the total number of participants experiencing serious adverse events was similar to placebo. However, the 2023 Cochrane review identified a statistically significant increase in non-fatal serious adverse events at moderate certainty, while a separate meta-analysis declaring no external funding reached a more reassuring conclusion — so the safety picture is contested rather than settled. Because it is a porcine-brain-derived biological preparation rather than a defined synthetic molecule, considerations that do not apply to synthetic peptides are relevant: controls on material from species susceptible to transmissible spongiform encephalopathy, hypersensitivity potential, batch-to-batch variability, and religious or dietary acceptability.

References